• X4 Pharmaceuticals Inc XFOR.OQ reported quarterly adjusted earnings of 4 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-7.80. The mean expectation of six analysts for the quarter was for a loss of $4.44 per share. Wall Street expected results to range from $-5.70 to -60 cents per share.

• Revenue was $28.81 million​; analysts expected $2.00 million.

• X4 Pharmaceuticals Inc's reported EPS for the quarter was 4 cents​.

• The company reported quarterly net income of $282 thousand.

• X4 Pharmaceuticals Inc shares had fallen by 47.1% this quarter and lost 83.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 30.6% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for X4 Pharmaceuticals Inc is $37.50

This summary was machine generated from LSEG data May 2 at 04:08 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)